CHINA RISUN GP (01907): Tianjin Binhai Energy & Development (000695.SZ) reported revenue of RMB819 million for the first three quarters, up 119.2% year on year.
China Risun Group (01907) announced the results of Binhai Energy (000695.SZ) for the nine months ended September 30, 2026, with operating revenue of RMB819 million, up 119.2% year on year; net loss attributable to shareholders of the listed company of RMB33.254 million; and basic loss per share of RMB0.1497.
CHINA RISUN GP (01907) announced the results of Tianjin Binhai Energy & Development (000695.SZ) for the nine months ended September 30, 2026, with operating revenue of RMB819 million, up 119.2% year on year; net loss attributable to shareholders of the listed company of RMB33.254 million; and basic loss per share of RMB0.1497.
Related Articles
Chipmore Semiconductor (07672) opens its IPO subscription from October 30 to November 5, planning a global offering of 107 million H shares and introducing cornerstone investors including GF Fund and Guohui Hong Kong.
Hemei Pharmaceutical-B (00054) is conducting a public offering from October 30 to November 4, planning to globally offer 55.21 million H shares and introducing cornerstone investors including GF Fund Management and China Universal Asset Management.
HK Stock Concept Tracker | Overseas BD Transaction Value for Domestic Innovative Drugs Expected to Exceed US$150 Billion in 2026; Overseas Commercialization Entering a Phase of Intensive Realization (with Concept Stocks)
Chipmore Semiconductor (07672) opens its IPO subscription from October 30 to November 5, planning a global offering of 107 million H shares and introducing cornerstone investors including GF Fund and Guohui Hong Kong.
Hemei Pharmaceutical-B (00054) is conducting a public offering from October 30 to November 4, planning to globally offer 55.21 million H shares and introducing cornerstone investors including GF Fund Management and China Universal Asset Management.
HK Stock Concept Tracker | Overseas BD Transaction Value for Domestic Innovative Drugs Expected to Exceed US$150 Billion in 2026; Overseas Commercialization Entering a Phase of Intensive Realization (with Concept Stocks)
